Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.2915
Abstract: Importance Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment… read more here.
Keywords: trial; cetuximab; months months; rechallenge ... See more keywords
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
Sign Up to like & getrecommendations! Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2020-001146
Abstract: Background No treatment demonstrated to improve survival in patients with recurrent glioblastoma (rGB) in a randomized trial. Combining axitinib with the programmed cell death ligand 1 blocking monoclonal antibody avelumab may result in synergistic activity… read more here.
Keywords: trial; treatment; cohort; recurrent glioblastoma ... See more keywords
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005813
Abstract: Background In preclinical studies, combining M9241 (a novel immunocytokine containing interleukin (IL)-12 heterodimers) with avelumab (anti-programmed death ligand 1 antibody) resulted in additive or synergistic antitumor effects. We report dose-escalation and dose-expansion results from the… read more here.
Keywords: plus avelumab; patients advanced; expansion part; expansion ... See more keywords
A phase I/II study of regorafenib (R) plus avelumab (A) in digestive tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps3125
Abstract: TPS3125Background: Several preclinical studies have shown that simultaneous blockade of programmed death(PD) 1/PD-L1 and neoangiogenesis induces synergistic anti-tumour effect in vivo. R is a multi... read more here.
Keywords: study regorafenib; avelumab digestive; digestive tumors; regorafenib plus ... See more keywords